We previously showed that an Fc-engineered CD19 antibody carrying a S239D/I332E mutation (DE-modification) showed enhanced effector cell-mediated killing of tumor cells and pronounced efficacy in BCP-ALL xenografts in vivo [19]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.